Zepbound sales soar, Ozempic sales miss, and CVS shakes up its leadership: Pharma news round upByBruce GilPublishedAugust 9, 2024
Getting your hands on Zepbound may get easier this year with new single-dose vialsByBruce GilPublishedAugust 8, 2024
Zepbound and Mounjaro sales are so hot Eli Lilly increased its full-year sales outlook by $3 billionByBruce GilPublishedAugust 8, 2024
One type of stock that didn't see huge losses today: Weight loss drug makersByBruce GilPublishedAugust 5, 2024
Zepbound is back on the shelves — but shortage isn't over yet, FDA saysByBruce GilPublishedAugust 5, 2024
Now playing Zepbound, the weight loss drug from Eli Lilly, found to help cut heart failure risksPublishedAugust 1, 2024
Now playing Eli Lilly's weight loss drug Zepbound could cut heart failure risks, trial findsByBruce GilPublishedAugust 1, 2024
People are overdosing on cheaper, off-brand versions of Ozempic, FDA warnsByBruce GilPublishedJuly 30, 2024
An Ozempic rival is getting closer to market — and it's hurting Novo Nordisk and Eli Lilly stockByBruce GilPublishedJuly 25, 2024
Hims & Hers has a 'long future' in selling off-brand Ozempic, former Novo Nordisk executive saysByBruce GilPublishedJuly 22, 2024
A new weight loss pill, Ozempic boosts protein sales, J&J's cancer drug: Pharma news roundupByBruce GilPublishedJuly 19, 2024
A new weight loss pill has Novo Nordisk and Eli Lilly shares fallingByBruce GilPublishedJuly 17, 2024
Johnson & Johnson's cancer drug Darzalex could replace Stelara as its best-sellerByBruce GilUpdatedJuly 17, 2024